Stem cell therapy for SLE is associated with signaling pathways such as the NF-κB [15], STAT [39], and Akt/GSK3β signaling pathways [22], which are related to the synthesis of downstream inflammatory mediators [15] and the regulation of T cells, including Th1, Th2, Treg, and Tfh cells [20, 22, 50]. The gene discussed is AKT1; the disease is systemic lupus erythematosus.